Search
Icosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIt is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. … Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).
Mangafodipir
go.drugbank.com/drugs/DB06796ApprovedInvestigationalWithdrawnMangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. … The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan.
Categories: Compounds used in a research, industrial, or household settingZuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalZuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. … Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin Receptor AntagonistsPegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigationalPegulicianine itself is a prodrug comprising three main fragments, one of which contains a fluorescence quencher that keeps the parent molecule optically inactive. … [L50537] The _in vivo_ enzymatic cleavage of pegulicianine results in two optically active fragments that emit a fluorescent signal that can be detected using a fluorescence imaging device.
Categories: Compounds used in a research, industrial, or household settingCX-052075
go.drugbank.com/drugs/DB31655ApprovedCX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1 … the SARS-CoV-2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose.
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnIopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. … On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082]
Categories: Compounds used in a research, industrial, or household settingCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalAn advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.
Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor AntagonistsAlefacept
go.drugbank.com/drugs/DB00092ApprovedWithdrawnImmunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells,...
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index